(269 days)
Not Found
No
The summary describes standard digital image acquisition and processing for an X-ray detector and associated software. There is no mention of AI, ML, or any related concepts like deep learning, neural networks, or algorithms that learn from data. The performance studies focus on traditional imaging metrics and phantom testing, not AI/ML performance metrics.
No
This device is a digital X-ray detector and associated software used for acquiring and processing mammographic images for screening and diagnosis; it does not directly treat or alleviate a disease or condition.
No
The VIVIX-M detector is used to acquire digital images for screening and diagnosis, but it is an image acquisition device, not a diagnostic device itself. The description states it "can be utilized to digitalize x-ray images and transfer for radiography diagnostic," implying that the diagnostic step follows the image acquisition.
No
The device description clearly includes hardware components (flat panel detectors, a-SI detectors) that are integral to the device's function of acquiring digital images from x-ray photons. While software is mentioned for data acquisition and processing, it is part of a larger hardware system.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The VIVIX-M detectors and associated software are used to acquire and process digital X-ray images of the breast for screening and diagnosis. This is an in vivo imaging technique, meaning it is performed on a living patient, not on a sample taken from the body.
- Intended Use: The intended use clearly states "mammographic applications to acquire digital images for screening and diagnosis," which aligns with medical imaging, not in vitro testing.
- Input Modality: The input modality is X-ray, which is a form of medical imaging, not a method for analyzing biological samples.
Therefore, the VIVIX-M system falls under the category of medical imaging devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
VIVIX-M detectors are flat panel detectors used in mammographic applications to acquire digital images for screening and diagnosis.
Product codes (comma separated list FDA assigned to the subject device)
MUE
Device Description
VIVIX-M, a series of flat panel detectors models named; FXMD-2430S, with imaging areas of 24cm x 30cm, 18cm x 24cm, respectively. The device intercepts x-ray photons and the scintillator emits visible spectrum photons that illuminate an array of photo (a-SI)-detectors that create electrical signals. After the electrical signals are generated, it is converted to digital value, and the Software acquires and processes the data values from the detector. The resulting digital images will be displayed on monitors. These devices should be integrated with an operating PC and an X-Ray generator. It can be utilized to digitalize x-ray images and transfer for radiography diagnostic.
VXvue Mammo is a digital X-ray imaging software designed for mammography applications. It acquires, processes, and transmits digital images from VIVIX-M detectors (FXMD-1008S and FXMD-2430S) while ensuring compliance with DICOM standards for seamless integration with PACS and other medical systems.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
X-Ray
Anatomical Site
Breast (Mammographic applications)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical laboratory testing was conducted to demonstrate substantial equivalence, including:
- Modulation Transfer Function (MTF): Both models demonstrated spatial resolution equivalent to the predicate device, with MTF values exceeding specified thresholds.
- Detective Quantum Efficiency (DQE): DQE values at all spatial frequencies were comparable to the predicate device, confirming equivalent imaging performance.
- Noise Power Spectrum (NPS): NPS results confirmed consistent noise performance across tested exposure levels.
- Dynamic Range Testing: Both models exhibited a wide dynamic range suitable for mammographic imaging.
- Image Erasure and Fading Test (Ghosting): No significant ghosting or residual artifacts were observed.
- Automatic Exposure Control (AEC) Performance: AEC performance met manufacturer-defined limits, ensuring consistent image quality.
- Phantom Testing (ACR, TE, CDMAM Phantoms): All tests demonstrated diagnostic image quality equivalent to or better than the predicate device.
- Patient Radiation Dose Measurement (Average Glandular Dose): Average glandular dose was within FDA-recommended limits for all scenarios.
A clinical image evaluation according to CDRH's 'Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Full-Field Digital Mammography System' was conducted, and the study confirmed that the new x-ray detectors VIVIX-M provide images of equivalent diagnostic capability to the predicate device, RSM 2430C and its results demonstrate substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
MTF, DQE, NPS, Dynamic Range, Ghosting, AEC Performance, Glandular Dose. Specific numerical values are provided for MTF and DQE for both the predicate and subject devices.
- Subject Device (FXMD-2430S) MTF: 54.9% at 3lp/mm, 33.1% at 5lp/mm
- Subject Device (FXMD-2430S) DQE: 59.0% at 3lp/mm, 42.5% at 5lp/mm
- Subject Device (FXMD-1008S) MTF: 52.7% at 3lp/mm, 32.7% at 5lp/mm
- Subject Device (FXMD-1008S) DQE: 65.8% at 3lp/mm, 46.9% at 5lp/mm
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1715 Full-field digital mammography system.
(a)
Identification. A full-field digital mammography system is a device intended to produce planar digital x-ray images of the entire breast. This generic type of device may include digital mammography acquisition software, full-field digital image receptor, acquisition workstation, automatic exposure control, image processing and reconstruction programs, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). The special control for the device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Full-Field Digital Mammography System.”See § 892.1(e) for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
January 16, 2025
Vieworks Co., Ltd. % Priscilla Chung Regulatory Affairs Consultant LK Consulting Group USA Inc. 18881 Von Karman Ave, STE 160 Irvine. California 92612
Re: K241113
Trade/Device Name: VIVIX-M Regulation Number: 21 CFR 892.1715 Regulation Name: Full-Field Digital Mammography System Regulatory Class: Class II Product Code: MUE Dated: October 18, 2024 Received: October 18, 2024
Dear Priscilla Chung:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory
2
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
D. Ryk
Daniel M. Krainak, Ph.D. Assistant Director DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K241113
Device Name VIVIX-M
Indications for Use (Describe)
VIVIX-M detectors are flat panel detectors used in mammographic applications to acquire digital images for screening and diagnosis.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) Summary (K241113)
This 510(k) summary information is prepared in accordance with 21 CFR807.92
1. Date Prepared [21 CFR 807.92(a) (1)]
1/15/2025
2. Submitter's Information [21 CFR 807.92(a) (1)]
| Name of Sponsor: | Vieworks Co., Ltd. |
|---|---|
| Address: | (Gwanyang-dong) 41-3, Burim-ro 170beon-gil,Dongan-gu |
| Anyang-si, Gyeonggi-do, 14055 Republic of Korea | |
| Contact Name: | Oh, Kevin / Regulatory Affairs Assistant Manager |
| Contact Number | +82-70-4466-3220 |
| Registration Number: | 3006013411, 3017585294 |
| Name of Manufacturer: | Same as Sponsor |
3. Trade Name, Common Name, Classification [21 CFR 807.92(a) (2)]
| Trade Name: | VIVIX-M |
|---|---|
| Model Name: | FXMD-2430S, FXMD-1008S |
| Common Name: | Digital Mammography System |
| Classification Name: | Full Field Digital, System, X-Ray, Mammographic |
| Classification Panel: | Radiology |
| Classification Regulation: | 21 CFR 892.1715 |
| Product Code: | MUE |
| Device Class: | 2 |
4. Identification of Predicate Device(s) [21 CFR 807.92(a) (3)]
| 510(k) Number: K170930 |
|---|
| Applicant: DRTECT Corporation |
| Trade Name: RSM 2430C |
| Common Name: Digital Mammography System |
| Classification Name: Full Field Digital, System, X-Ray, Mammographic |
| Classification Panel: Radiology |
| Classification Regulation: 21 CFR 892. 1715 |
| Product Code: MUE |
| Device Class: 2 |
| Decision Date: 04/17/2017 |
| Type: Traditional |
5
5. Description of the Device [21 CFR 807.92(a) (4)]
General Description O
VIVIX-M, a series of flat panel detectors models named; FXMD-2430S, with imaging areas of 24cm x 30cm, 18cm x 24cm, respectively. The device intercepts x-ray photons and the scintillator emits visible spectrum photons that illuminate an array of photo (a-SI)-detectors that create electrical signals. After the electrical signals are generated, it is converted to digital value, and the Software acquires and processes the data values from the detector. The resulting digital images will be displayed on monitors. These devices should be integrated with an operating PC and an X-Ray generator. It can be utilized to digitalize x-ray images and transfer for radiography diagnostic.
VXvue Mammo is a digital X-ray imaging software designed for mammography applications. It acquires, processes, and transmits digital images from VIVIX-M detectors (FXMD-1008S and FXMD-2430S) while ensuring compliance with DICOM standards for seamless integration with PACS and other medical systems.
6. Indications for Use [21 CFR 807.92(a)(5)]
VIVIX-M detectors are flat panel detectors used in mammographic applications to acquire digital images for screening and diagnosis.
7. Technological Characteristics [21 CFR 807.92(a) (6)]
Compared with the predicate, devices show the technological characteristics of the proposed VIVIX-M device to be substantially equivalent to the predicate device. The proposed devices are functionally identical to the predicate device.
| Contents | Requirements |
|---|---|
| Tube Type | Rotating anode or Stationary |
| Target | Molybdenum, Rhodium or Tungsten |
| Bucky Size | 18cm x 24cm or 24cm x 30cm |
| Grid | Moving |
| Filter | Mo, Rh |
| kVp | 20 ~ 35 (Mo, W), 28 ~ 39 (Rh) |
| mAs | 3 ~ 500 |
8. Integrated System Requirements
- Software Requirement
: These detectors are compatible with VXvue Mammo (V 1.0)
9. Substantial Equivalence [21 CFR 807.92(b)(1) and 807.92]
When compared to the predicate device (K170930), the VIVIX-M presented in this submission is substantially equivalent:
- Intended Use
- Technological characteristics
- Operating principle
- Design features
- Communication Method
- Scintillator Materials
- Resolution
6
There is similar performance as follow.
- Performance (MTF)
- Performance (DQE)
There are no significant difference between the VIVIX-M and the predicate device that would adversely affect the use of the product. It is substantially equivalent to the predicate device in design, function, materials, operational principles and intended use.
| Parameter | Predicate Device | Subject Device | Equivalence |
|---|---|---|---|
| 510(k) Number | K170930 | K241113 | - |
| Manufacturer | DRTECH Corporation | Vieworks Co., Ltd. | - |
| Model Name | RSM 2430C | FXMD-2430S | - |
| Classification Name | Full Field Digital, System, X-ray, Mammographic | Equivalent | |
| Classification Panel | Radiology | Equivalent | |
| Classification | |||
| Regulation | 21 CFR 892.1715 | Equivalent | |
| Product Code | MUE | Equivalent | |
| Device Class | 2 | Equivalent | |
| Indications for Use | The RSM 2430C is a detector | ||
| indicated for use in screening | |||
| and diagnostic | |||
| mammography. | VIVIX-M detectors are flat | ||
| panel detectors used in | |||
| mammographic applications | |||
| to acquire digital images for | |||
| screening and diagnosis. | Substantially | ||
| Equivalent | |||
| Scintillating Material | Cesium lodide | Thallium doped Cesium | |
| lodide | Substantially | ||
| Equivalent | |||
| Pixel Pitch (µm) | 76 | 75 | Substantially |
| Equivalent | |||
| Pixel Matrix | 3072x3840 | 3072×3840 | Equivalent |
| Dimensions (H x W x D) | 327.15mm x 253.75mm x | ||
| 14.2mm | 254.6 mm × 327.6 mm × | ||
| 15.0 mm | Substantially | ||
| Equivalent | |||
| Weight (kg) | 1.5 | FXMD-1008S: 1.0 | |
| FXMD-2430S: 1.2 | - | ||
| Rated Power Supply | DC +12V | DC +24V, Max. 0.75A | - |
| Power Consumption | 30W | Max. 18W | - |
| Data Output and Software | |||
| Features | Rconsole 1 | VXvue Mammo | - |
| MTF | 70% at 2lp/mm | ||
| 30% at 5lp/mm | 54.9% at 3lp/mm | ||
| 33.1% at 5lp/mm | Substantially | ||
| Equivalent | |||
| DQE | 43% at 2lp/mm | ||
| 30% at 5lp/mm | 59.0% at 3lp/mm | ||
| 42.5% at 5lp/mm | Substantially | ||
| Equivalent |
7
| Parameter | Predicate Device | Subject Device | Equivalence |
|---|---|---|---|
| 510(k) Number | K170930 | K241113 | - |
| Manufacturer | DRTECH Corporation | Vieworks Co., Ltd. | - |
| Model Name | RSM 2430C | FXMD-1008S | - |
| Common Name | Digital Flat Panel X-ray Detector | Equivalent | |
| Classification Name | Solid State X-Ray Imager (Flat Panel/Digital Imager) | Equivalent | |
| Classification Panel | Radiology | Equivalent | |
| Classification | |||
| Regulation | 21 CFR 892.1715 | Equivalent | |
| Product Code | MUE | Equivalent | |
| Device Class | 2 | Equivalent | |
| Indications for Use | The RSM 2430C is a detector | ||
| indicated for use in | |||
| screening and diagnostic | |||
| mammography. | VIVIX-M detectors are flat | ||
| panel detectors used in | |||
| mammographic applications | |||
| to acquire digital images for | |||
| screening and diagnosis. | Substantially | ||
| Equivalent | |||
| Scintillating Material | Cesium lodide | Thallium doped Cesium | |
| lodide | Substantially | ||
| Equivalent | |||
| Pixel Pitch (μm) | 76 | 75 | Substantially |
| Equivalent | |||
| Pixel Matrix | 3072x3840 | 3072×2304 | Substantially |
| Equivalent | |||
| Dimensions (H x W x D) | 327.15mm x 253.75mm x | ||
| 14.2mm | 254.6 mm × 327.6 mm × | ||
| 15.0 mm | Substantially | ||
| Equivalent | |||
| Weight (kg) | 1.5 | FXMD-1008S: 1.0 | |
| FXMD-2430S: 1.2 | - | ||
| Rated Power Supply | DC +12V | DC +24V, Max. 0.75A | - |
| Data Output and Software | |||
| Features | Rconsole 1 | VXvue Mammo | - |
| MTF | 70% at 2lp/mm | ||
| 30% at 5lp/mm | 52.7% at 3lp/mm | ||
| 32.7% at 5lp/mm | Substantially | ||
| Equivalent | |||
| DQE | 43% at 2lp/mm | ||
| 30% at 5lp/mm | 65.8% at 3lp/mm | ||
| 46.9% at 5lp/mm | Substantially | ||
| Equivalent |
8
10. Summary of Non-Clinical Data
This section provides a high-level summary of the non-clinical laboratory testing conducted to demonstrate substantial equivalence between the subject devices (VIVIX-M models FXMD-1008S and FXMD-2430S) and the predicate device (K170930). The testing complies with FDA-recognized standards and the recommendations outlined in the Full Field Digital Mammography System - Class II Special Controls Guidance for Industry and FDA Staff (March 27, 2012).
Testing Summary
The following non-clinical tests were performed to evaluate the performance of the subject devices:
1) Modulation Transfer Function (MTF):
- Purpose: To assess spatial resolution. ●
- . Protocol: Conducted per IEC 62220-1-2:2007 standards using a tungsten edge phantom.
- Results: Both models demonstrated spatial resolution equivalent to the predicate device, ● with MTF values exceeding specified thresholds.
2) Detective Quantum Efficiency (DQE):
- Purpose: To evaluate signal-to-noise ratio transfer efficiency. ●
- Protocol: Measurements followed IEC 62220-1-2:2007 guidelines using standard clinical exposure conditions.
- . Results: DQE values at all spatial frequencies were comparable to the predicate device, confirming equivalent imaging performance.
Noise Power Spectrum (NPS): 3)
- Purpose: To analyze noise characteristics.
- Protocol: Conducted under seven exposure levels as per IEC 62220-1-2.
- Results: NPS results confirmed consistent noise performance across tested exposure levels.
4) Dynamic Range Testing:
- Purpose: To determine the range of exposure levels without saturation artifacts. ●
- Protocol: Based on sensitometric response data from IEC 62220-1-2.
- Results: Both models exhibited a wide dynamic range suitable for mammographic imaging.
Image Erasure and Fading Test (Ghosting): ട്)
- Purpose: To assess residual image effects after repeated exposures.
- Protocol: Evaluated using a Pb phantom under specified conditions.
- . Results: No significant ghosting or residual artifacts were observed.
ର) Automatic Exposure Control (AEC) Performance:
- Purpose: To verify compatibility with AEC systems for varying breast thicknesses.
- . Protocol: Tested across PMMA thicknesses from 20mm to 70mm in standard and magnification modes.
- Results: AEC performance met manufacturer-defined limits, ensuring consistent image quality.
7) Phantom Testing (ACR, TE, CDMAM Phantoms):
- Purpose: To evaluate image quality metrics such as detectability of specks, fibers, and masses.
- . Protocols:
- ACR Phantom tested for visibility of structures under automatic exposure settings. .
- TE Phantom assessed line pair resolution and mass detection. ●
- CDMAM Phantom analyzed contrast-detail thresholds.
- . Results: All tests demonstrated diagnostic image quality equivalent to or better than the predicate device.
-
- Patient Radiation Dose Measurement (Average Glandular Dose):
- Purpose: To ensure compliance with dose safety limits while maintaining image quality. ●
- Protocol: Conducted under MQSA-compliant conditions simulating compressed breast thicknesses (30%, 50%, and 70% glandular tissue compositions).
9
- Results: Average glandular dose was within FDA-recommended limits for all scenarios.
Standards and Guidance Referenced
The following standards and guidance documents were utilized:
- IEC 62220-1-2:2007 (Medical Electrical Equipment – Characteristics of Digital X-Ray Imaging Devices).
- Full Field Digital Mammography System – Class II Special Controls Guidance for Industry and FDA Staff, March 27, 2012.
- MQSA requirements for average glandular dose limits.
Conclusion
The non-clinical testing results demonstrate that the VIVIX-M models FXMD-1008S and FXMD-2430S are substantially equivalent to the predicate device in terms of safety, effectiveness, and performance. The devices comply with applicable FDA-recognized consensus standards, ensuring suitability for their intended use in mammographic imaging.
11. Summary of Clinical Data
A clinical image evaluation according to CDRH's 'Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Full-Field Digital Mammography System' was conducted, and the study confirmed that the new x-ray detectors VIVIX-M provide images of equivalent diagnostic capability to the predicate device, RSM 2430C and its results demonstrate substantial equivalence.
12. Conclusion [21 CFR 807.92(b) (3)]
The VIVIX-M Digital X-ray detectors are substantially equivalent to the currently marketed and predicate devices (K170930) in terms of design features, fundamental scientific technology, indications for use, and safety and effectiveness.
Additionally, Substantial equivalence was demonstrated through the non-clinical performance, which complied with the requirements specified in the international and FDA-recognized consensus standards, IEC60601-1, IEC 60601-1-2, and the clinical test, which complied with the requirements specified in the CDRH's 'Class II Special Controls Guidance Document: Full-Field Digital Mammography System'.
The results of these tests demonstrate that VIVIX-M Digital X-ray detectors meets the acceptance criteria and is adequate for this intended use. The comparison of technological characteristics, non-clinical performance data, safety testing, and clinical image concurrence data demonstrates that the device is as safe, as effective, and performance is substantially equivalent to the predicate device as well.